BioWorld

Jan. 30, 2007

MDS Acquiring Tools Company Molecular Devices For $615M

MDS Inc. plans to broaden its position in life sciences research through a $615 million all-cash acquisition of Molecular Devices Corp. (BioWorld Today) Read More

ISC Completes Reverse Merger With BTHC III, Raises $11.2M

Microarray Studies Often Very Good,' But Analysis Can Lag

Icagen Brings In $22M Via Sale Of Stock And Warrants

Abingworth Closes $587M Fund For Broad Range Of Investments

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...